A new therapy paradigm for prostate cancer founded on clinical Observations

Clinical Cancer Research

Volumn 16, Issue 4, 2010, Pages 1100-1107

  Efstathiou, Eleni ^a,b   Logothetis, Christopher J ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; AFLIBERCEPT; ANDROSTENEDIONE; ANTINEOPLASTIC AGENT; AP 11014; AP 12009; ATRASENTAN; BEVACIZUMAB; CILENGITIDE; CP 751871; CYTOCHROME P450 17; DASATINIB; DEFOROLIMUS; DENOSUMAB; DOCETAXEL; DOVITINIB; ESTRAMUSTINE; EVEROLIMUS; GDC 0449; GEFITINIB; IMATINIB; IMCA 12; LENALIDOMIDE; MDV 3100; MITOXANTRONE; MK 0752; MONOCLONAL ANTIBODY LM 609; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; PREDNISONE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; VATALINIB; ZIBOTENTAN;

ADULT; ANDROGEN DEPRIVATION THERAPY; ANTIANGIOGENIC ACTIVITY; BONE METASTASIS; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; HUMAN; MALE; MICROENVIRONMENT; MULTIPLE CYCLE TREATMENT; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

BONE NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 76749108148     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1215     Document Type: Review

References (57)

1. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098-109.
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
3. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
4. Ross RW, Beer TM, Jacobus S, et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 2008;112:521-6.
5. Ferrero JM, Chamorey E, Oudard S, et al. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. Cancer 2006;107:738-45.
6. Marur S, Eliason J, Heilbrun L, et al. Phase II trial of oral capecitabine (C) and weekly docetaxel (D) in patients with metastatic androgen independent prostate cancer (AIPC) [Abstract]. J Clin Oncol 2007; 25:5121.
7. Millikan RE, Wen S, Pagliaro LC, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008;26:5936-42.
8. Mackler NJ, Pienta KJ, Dunn RL, et al. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. Clin Genitourin Cancer 2007;5:318-22.
9. Mathew P, Thall PF, Bucana CD, et al. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 2007;13: 5816-24.
10. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxol plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22:2532-9.
11. Chi KN, Chin JL, Winquist E, et al. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008;180:565-70.
12. Pettaway CA, Pisters LL, Troncoso P, et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: Feasibility and preliminary results. J Clin Oncol 2000;18:1050-7.
13. Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11:5233-40.
14. Hussain M, Smith D, El-Rayes B, et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology 2003;61:774-80.
15. Dreicer R, Magi-Galluzzi C, Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004;63:1138-42.
16. Shepard DR, Dreicer R, Garcia J, et al. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. J Urol 2009;181:1672-7.
17. Eastham JA, Kelly WK, Grossfeld GD, et al, Cancer and Leukemia Group B (CALGB) 90203. A randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003;62:55-62.
18. Schmidt JD, Gibbons RP, Murphy GP, Bartolucci A. Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation. Eur Urol 1996;29:425-33.
19. Wang J, Halford S, Rigg A, et al. Adjuvant mitoxantrone chemotherapy in advanced prostate cancer. BJU Int 2000;86:675-80.
20. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial. Lancet 2001;357:336-41.
21. Tu SM, Kim J, Pagliaro LC, et al. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 2005; 23:7904-10.
22. 153Sm repetitively administered for castrate metastatic prostate cancer (CMPC). J Clin Oncol 2008;25:5152.
23. 153Sm-lexidronam (Sam) in androgen-independent prostate cancer (AIPC). J Clin Oncol 2008;26: 5132.
24. Logothetis CJ, Navone NM, Lin SH. Understanding the biology of bone metastases: Key to the effective treatment of prostate cancer. Clin Cancer Res 2008;14:1599-602.
25. Chung LW, Huang WC, Sung SY, et al. Stromal-epithelial interaction in prostate cancer progression. Clin Genitourin Cancer 2006;5: 162-70.
26. Ingber DE. Can cancer be reversed by engineering the tumor micro-environment? Semin Cancer Biol 2008;18:356-64.
27. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005;7:513-20.
28. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007;7:139-47.
29. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-49.
30. Cunha GR, Fujii H, Neubauer BL, et al. Epithelial-mesenchymal interactions in prostatic development: I. Morphological observations of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder. J Cell Biol 1983;96:1662-70.
31. Cunha GR, Donjacour AA, Cooke PS, et al. The endocrinology and developmental biology of the prostate. Endocr Rev 1987;8: 338-62.
32. Chung LW, Zhau HE, Ro JY. Morphologic and biochemical alterations in rat prostatic tumors induced by fetal urogenital sinus mesenchyme. Prostate 1990;17:165-74.
33. Chung LWK. Fibroblasts are critical determinants in prostatic cancer growth and dissemination. Cancer Metastasis Rev 1991;10:263-74.
34. Hayward SW, Wang Y, Cao M, et al. Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res 2001;61:8135-42.
35. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001;166:2472-83.
36. Li ZG, Mathew P, Yang J, et al. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 2008;118:2697-710.
37. Niu Y, Altuwaijri S, Lai KP, et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A 2008;105:12182-7.
38. Attard G, Reid AH, Olmos D, de Bono JS. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009;69:4937-40.
39. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110: 1959-66.
40. Lin AM, Rini BI, Weinberg V, et al. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int 2006;98:763-9.
41. Bailey JM, Singh PK, Hollingsworth MA. Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. J Cell Biochem 2007;102:829-39.
42. Abate-Shen C, Shen MM. FGF signaling in prostate tumorigenesisnew insights into epithelial-stromal interactions. Cancer Cell 2007; 12:495-7.
43. Acevedo VD, Gangula RD, Freeman KW, et al. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 2007;12:559-71.
44. Memarzadeh S, Xin L, Mulholland DJ, et al. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 2007;12:572-85.
45. Karhadkar SS, Bova GS, Abdallah N, et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004;431: 707-12.
46. Sanchez P, Hernández AM, Stecca B, et al. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci U S A 2004;101:12561-6.
47. Efstathiou E, Troncoso P, Wen S, et al. Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 2007;13:1224-31.
48. Gordon JA, Sodek J, Hunter GK, Goldberg HA. Bone sialoprotein stimulates focal adhesion-related signaling pathways: role in migration and survival of breast and prostate cancer cells. J Cell Biochem 2009;107:1118-28.
49. Jones E, Pu H, Kyprianou N. Targeting TGF-β in prostate cancer: therapeutic possibilities during tumor progression. Expert Opin Ther Targets 2009;13:227-34.
50. Yang S, Pham LK, Liao CP, Frenkel B, Reddi AH, Roy-Burman P. A novel bone morphogenetic protein signaling in heterotypic cell interactions in prostate cancer. Cancer Res 2008;68:198-205.
51. Feeley BT, Gamradt SC, Hsu WK, et al. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 2005;20:2189-99.
52. Maple H, Dasgupta P. The role of 'notch' in urological cancers. BJU Int 2009;104:1-2.
53. Chi KN, Bjartell A, Dearnaley D, et al. Castration-resistant prostate cancer: From new pathophysiology to new treatment targets. Eur Urol 2009;56:594-605.
54. Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008;68:3323-33.
55. Kuniyasu H, Ukai R, Johnston D, et al. The relative mRNA expression levels of matrix metalloproteinase to E-cadherin in prostate biopsy specimens distinguishes organ-confined from advanced prostate cancer at radical prostatectomy. Clin Cancer Res 2003;9: 2185-94.
56. Guérin O, Formento P, Lo Nigro C, et al. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel: A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 2008;134:51-7.
57. Bajaj GK, Zhang Z, Garrett-Mayer E, et al. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology 2007;69:526-31.